ROMANO KATHRYN 4
4 · Krystal Biotech, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Krystal Biotech (KRYS) CAO Kathryn Romano Exercises Options, Sells 12,500
What Happened
- Kathryn Romano, Chief Accounting Officer of Krystal Biotech (KRYS), exercised 12,500 stock options at $63.55 each (cost = $794,375) on Feb 9, 2026 (transaction code M). The 12,500 shares from that exercise were sold the same day in multiple open-market trades (transaction code S) for aggregate proceeds of approximately $3,401,705. In addition, Romano made a bona fide gift of 750 shares to a charitable donor-advised fund (transaction code G).
Key Details
- Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (timely filing).
- Exercise: 12,500 shares @ $63.55 (total cost $794,375).
- Sales: 12,500 shares sold across multiple trades at weighted average prices by lot (reported lot prices range roughly $270.01–$277.88); total proceeds ≈ $3.40M.
- Gift: 750 shares donated to a donor-advised fund (bona fide charitable gift).
- Footnotes of note:
- Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 6, 2025 (plan terminates Aug 31, 2026) — indicates pre-arranged trades.
- The underlying options vested ratably over a four-year period beginning Feb 28, 2022.
- Multiple-sale price ranges are reported; the filer will provide per-trade breakdown on request.
- Shares owned after the transaction: not specified in the provided filing excerpt.
Context
- This was an option exercise followed by same-day sales under a 10b5-1 plan (M = option exercise; S = sale; G = gift). Exercising options and immediately selling the delivered shares is a common, non-pecuniary way for insiders to realize gains; the charitable gift does not signal trading sentiment. The filing shows execution details and the 10b5-1 plan disclosure, which indicates the trades were pre-planned rather than opportunistic.
Insider Transaction Report
Form 4
ROMANO KATHRYN
Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-09$63.55/sh+12,500$794,375→ 31,818 total - Sale
Common Stock
[F2]2026-02-09$270.56/sh−2,000$541,116→ 29,818 total - Sale
Common Stock
[F3]2026-02-09$271.66/sh−5,700$1,548,477→ 24,118 total - Sale
Common Stock
[F4]2026-02-09$272.51/sh−2,824$769,562→ 21,294 total - Sale
Common Stock
[F5]2026-02-09$273.71/sh−928$254,001→ 20,366 total - Sale
Common Stock
[F6]2026-02-09$274.64/sh−552$151,601→ 19,814 total - Sale
Common Stock
[F7]2026-02-09$275.68/sh−400$110,272→ 19,414 total - Sale
Common Stock
[F8]2026-02-09$277.88/sh−96$26,676→ 19,318 total - Gift
Common Stock
[F9]2026-02-09−750→ 18,568 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F10]2026-02-09−12,500→ 12,500 totalExercise: $63.55Exp: 2032-02-27→ Common Stock (12,500 underlying)
Footnotes (10)
- [F1]The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
- [F10]The options vested ratably over a four-year period beginning on February 28, 2022.
- [F2]The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F6]The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F7]The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F8]The transaction was executed in a single trade.
- [F9]Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund.
Signature
/s/ Kathryn Romano|2026-02-11